Tags

Type your tag names separated by a space and hit enter

Beyond the learning curve of the Retzius-sparing approach for robot-assisted laparoscopic radical prostatectomy: oncologic and functional results of the first 200 patients with ≥ 1 year of follow-up.
Eur Urol. 2013 Dec; 64(6):974-80.EU

Abstract

BACKGROUND

Robot-assisted laparoscopic radical prostatectomy (RARP) has become the main surgical option for localized prostate cancer. We recently developed a new approach for RARP, passing through the pouch of Douglas and avoiding all the Retzius structures involved in continence and potency preservation.

OBJECTIVE

To report the functional and oncologic results of our first 200 patients operated on using this new approach.

DESIGN, SETTING, AND PARTICIPANTS

This was a prospective, noncontrolled case series including the first 200 consecutive patients undergoing this kind of surgery (January the 1st, 2010 to December the 31st, 2011).

SURGICAL PROCEDURE

Retzius-sparing RARP.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS

All perioperative, oncologic, and functional data were prospectively recorded. Potency was defined as an International Index of Erectile Function-5 questionnaire score >17; continence was defined as use of no pad or of one safety liner. Oncologic results were reported as positive surgical margins (PSM) and 1-yr biochemical disease-free survival (1y-bDFS). Recurrence was defined as a repeated prostate-specific antigen >0.2 ng/ml. Complications were graded according to the Clavien-Dindo system. The first 100 patients (group 1) were compared with the second 100 (group 2) to evaluate the learning curve effects.

RESULTS AND LIMITATIONS

The median patient age was 65 yr. Comparing the two groups, transfusions were needed in 8% versus 4% of cases in groups 1 and 2, respectively (p=0.02). There was one Clavien-Dindo grade 3b in group 1 versus one grade 3a complication in group 2. In patients with pT2 disease, PSMs were recorded in 22.4% of those in group 1 versus 10.1% in group 2 (p=0.045). 1y-bDFS was 89% in group 1 versus 92% in group 2. For groups 1 and 2, respectively, immediate continence was reached in 92% versus 90% of patients, and the 1-yr continence rate was 96% versus 96%. Considering the 77 potent patients aged <65 yr who underwent bilateral intrafascial nerve-sparing surgery, 40.4% of those in group 1 versus 40% of those in group 2 reached their first intercourse within 1 mo; at 1 yr of follow-up, these figures had increased to 81% versus 71%, respectively (p=0.162). The main limitation of this study is its noncontrolled nature.

CONCLUSIONS

We demonstrated Retzius-sparing RARP to be oncologically safe and to result in high early continence and potency rates. Long-term, prospective, comparative, and possibly randomized studies are needed.

Authors+Show Affiliations

Department of Urology, Niguarda Ca' Granda Hospital, Milan, Italy. Electronic address: antoniogalfano@gmail.com.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23856036

Citation

Galfano, Antonio, et al. "Beyond the Learning Curve of the Retzius-sparing Approach for Robot-assisted Laparoscopic Radical Prostatectomy: Oncologic and Functional Results of the First 200 Patients With ≥ 1 Year of Follow-up." European Urology, vol. 64, no. 6, 2013, pp. 974-80.
Galfano A, Di Trapani D, Sozzi F, et al. Beyond the learning curve of the Retzius-sparing approach for robot-assisted laparoscopic radical prostatectomy: oncologic and functional results of the first 200 patients with ≥ 1 year of follow-up. Eur Urol. 2013;64(6):974-80.
Galfano, A., Di Trapani, D., Sozzi, F., Strada, E., Petralia, G., Bramerio, M., Ascione, A., Gambacorta, M., & Bocciardi, A. M. (2013). Beyond the learning curve of the Retzius-sparing approach for robot-assisted laparoscopic radical prostatectomy: oncologic and functional results of the first 200 patients with ≥ 1 year of follow-up. European Urology, 64(6), 974-80. https://doi.org/10.1016/j.eururo.2013.06.046
Galfano A, et al. Beyond the Learning Curve of the Retzius-sparing Approach for Robot-assisted Laparoscopic Radical Prostatectomy: Oncologic and Functional Results of the First 200 Patients With ≥ 1 Year of Follow-up. Eur Urol. 2013;64(6):974-80. PubMed PMID: 23856036.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Beyond the learning curve of the Retzius-sparing approach for robot-assisted laparoscopic radical prostatectomy: oncologic and functional results of the first 200 patients with ≥ 1 year of follow-up. AU - Galfano,Antonio, AU - Di Trapani,Dario, AU - Sozzi,Francesco, AU - Strada,Elena, AU - Petralia,Giovanni, AU - Bramerio,Manuela, AU - Ascione,Assunta, AU - Gambacorta,Marcello, AU - Bocciardi,Aldo Massimo, Y1 - 2013/07/08/ PY - 2013/04/28/received PY - 2013/06/24/accepted PY - 2013/7/17/entrez PY - 2013/7/17/pubmed PY - 2014/7/1/medline KW - Douglas pouch KW - Learning curve KW - Prostate cancer KW - RARP KW - Robot-assisted laparoscopic radical prostatectomy SP - 974 EP - 80 JF - European urology JO - Eur. Urol. VL - 64 IS - 6 N2 - BACKGROUND: Robot-assisted laparoscopic radical prostatectomy (RARP) has become the main surgical option for localized prostate cancer. We recently developed a new approach for RARP, passing through the pouch of Douglas and avoiding all the Retzius structures involved in continence and potency preservation. OBJECTIVE: To report the functional and oncologic results of our first 200 patients operated on using this new approach. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective, noncontrolled case series including the first 200 consecutive patients undergoing this kind of surgery (January the 1st, 2010 to December the 31st, 2011). SURGICAL PROCEDURE: Retzius-sparing RARP. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: All perioperative, oncologic, and functional data were prospectively recorded. Potency was defined as an International Index of Erectile Function-5 questionnaire score >17; continence was defined as use of no pad or of one safety liner. Oncologic results were reported as positive surgical margins (PSM) and 1-yr biochemical disease-free survival (1y-bDFS). Recurrence was defined as a repeated prostate-specific antigen >0.2 ng/ml. Complications were graded according to the Clavien-Dindo system. The first 100 patients (group 1) were compared with the second 100 (group 2) to evaluate the learning curve effects. RESULTS AND LIMITATIONS: The median patient age was 65 yr. Comparing the two groups, transfusions were needed in 8% versus 4% of cases in groups 1 and 2, respectively (p=0.02). There was one Clavien-Dindo grade 3b in group 1 versus one grade 3a complication in group 2. In patients with pT2 disease, PSMs were recorded in 22.4% of those in group 1 versus 10.1% in group 2 (p=0.045). 1y-bDFS was 89% in group 1 versus 92% in group 2. For groups 1 and 2, respectively, immediate continence was reached in 92% versus 90% of patients, and the 1-yr continence rate was 96% versus 96%. Considering the 77 potent patients aged <65 yr who underwent bilateral intrafascial nerve-sparing surgery, 40.4% of those in group 1 versus 40% of those in group 2 reached their first intercourse within 1 mo; at 1 yr of follow-up, these figures had increased to 81% versus 71%, respectively (p=0.162). The main limitation of this study is its noncontrolled nature. CONCLUSIONS: We demonstrated Retzius-sparing RARP to be oncologically safe and to result in high early continence and potency rates. Long-term, prospective, comparative, and possibly randomized studies are needed. SN - 1873-7560 UR - https://www.unboundmedicine.com/medline/citation/23856036/Beyond_the_learning_curve_of_the_Retzius_sparing_approach_for_robot_assisted_laparoscopic_radical_prostatectomy:_oncologic_and_functional_results_of_the_first_200_patients_with_≥_1_year_of_follow_up_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0302-2838(13)00661-1 DB - PRIME DP - Unbound Medicine ER -